First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens

Abstract Background Sub-Saharan African countries are transitioning to dolutegravir-based regimens, even for patients with extensive previous drug exposure, including first-generation integrase strand-transfer inhibitors (INSTI) such as raltegravir. Such exposure might have implications on cross-res...

Full description

Bibliographic Details
Main Authors: Joseph Fokam, Desire Takou, Ezechiel Ngoufack Jagni Semengue, Georges Teto, Grace Beloumou, Beatrice Dambaya, Maria-Mercedes Santoro, Leonella Mossiang, Serge Clotaire Billong, Fatim Cham, Samuel Martin Sosso, Edith Saounde Temgoua, Aubin Joseph Nanfack, Sylvie Moudourou, Nelly Kamgaing, Rachel Kamgaing, Joelle Nounouce Ngako Pamen, Mireille Mpoudi Ngole Etame, Anne-Cecile Z.-K. Bissek, Jean-Bosco N. Elat, Emmanuel Eben Moussi, Vittorio Colizzi, Carlo-Federico Perno, Alexis Ndjolo, On behalf of the VIROFORUM
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Antimicrobial Resistance and Infection Control
Subjects:
HIV drug resistance
Integrase inhibitors
Protease inhibitors
Viral tropism
Cameroon
Online Access:http://link.springer.com/article/10.1186/s13756-020-00799-2

Internet

http://link.springer.com/article/10.1186/s13756-020-00799-2

Similar Items